Open AccessMajor pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report
Author(s) -
Fu Yang,
Wang PeiPei,
He Du,
Zheng Yue,
Ding ZhenYu
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13905
Subject(s) - medicine , pathological , immunotherapy , chemoradiotherapy , neoadjuvant therapy , complete response , oncology , carcinoma , esophagectomy , spindle cell carcinoma , chemotherapy , esophageal cancer , cancer , breast cancer
Esophageal spindle cell carcinoma (ESpCC) is a rare subtype of esophageal carcinoma, accounting for 1% of all esophageal malignancies. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 60‐year‐old male with initially unresectable ESpCC, in which platinum‐based concurrent chemoradiotherapy was unsuccessful. He was subsequently treated with neoadjuvant immunotherapy and after surgery achieved a complete pathological response; therefore, neoadjuvant immunotherapy might be a novel option for ESpCC patients.